Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study
The ChAdOx1 nCoV-19 fourth dose is well tolerated and boosts humoral immunity; this was evident as an increased humoral response across multiple variants of concern. These data support its use as a booster dose against SARS-CoV-2 infection.
Authors
- Teresa Lambe (ORCID: https://orcid.org/0000-0001-7711-897X)
- Yama F Mujadidi (ORCID: https://orcid.org/0000-0002-2342-8531)
- Federica Cappuccini (ORCID: https://orcid.org/0000-0003-4124-1591)
- Shuo Feng (ORCID: https://orcid.org/0000-0001-7855-0991)
- Agnes Eordogh
- Hardeep Singh Gill
- Elizabeth Clutterbuck (ORCID: https://orcid.org/0000-0003-1701-1390)
- Sally Felle (ORCID: https://orcid.org/0000-0001-7855-4482)
- Parvinder K. Aley (ORCID: https://orcid.org/0000-0002-0749-8329)
- Iyiola Olatunji Oladunjoye (ORCID: https://orcid.org/0000-0002-6760-5448)
- Narges Ebrahimi (ORCID: https://orcid.org/0000-0002-8953-6842)
- Andrew J. Pollard (ORCID: https://orcid.org/0000-0001-7361-719X)
- Sagida Bibi (ORCID: https://orcid.org/0000-0002-0855-2737)
- Justin Green
- Saul N. Faust (ORCID: https://orcid.org/0000-0003-3410-7642)
- Nelly Owino (ORCID: https://orcid.org/0000-0003-2325-5658)
- Merryn Voysey (ORCID: https://orcid.org/0000-0001-6324-6559)
- Kerry Conlin
- Hannah R. Robinson (ORCID: https://orcid.org/0000-0002-9150-8015)
- Emma Plested
- Arabella Stuart
Institutions
- University of Oxford (GB)
- AstraZeneca (South Korea) (KR)
- NIHR Southampton Biomedical Research Centre (GB)
- Oxford BioMedica (United Kingdom) (GB)
- Science Oxford (GB)
Publication Details
- Journal
- Journal of Infection
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1016/j.jinf.2025.106423
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- National Institute for Health and Care Research